We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium‐glucose cotransporter 2 inhibitors? A correlation meta‐analysis.
- Authors
Diallo, Alhassane; Carlos‐Bolumbu, Miguel; Galtier, Florence
- Abstract
This article discusses the use of composite cardiovascular death or hospitalization for heart failure (HHF) as a surrogate endpoint for mortality in patients treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors. The study conducted a systematic review and meta-analysis of 12 trials involving 85,893 patients to determine the correlation between HHF or cardiovascular (CV) death and all-cause mortality. The results showed that the composite of HHF or CV death can serve as a valid surrogate endpoint for all-cause mortality in patients treated with SGLT2 inhibitors. This finding has important implications for future clinical trials and drug development programs.
- Subjects
SODIUM-glucose cotransporter 2 inhibitors; CARDIOVASCULAR disease related mortality; HEART failure; ASYMMETRIC dimethylarginine; GLUCOSE; MORTALITY; HOSPITAL care
- Publication
Diabetes, Obesity & Metabolism, 2024, Vol 26, Issue 1, p392
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.15320